Blackstone Inc’s Definium Therapeutics DFTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$26.4M Buy
561,612
+52,944
+10% +$1.31M 0.08% 67
2026
Q1
$9.61M Sell
508,668
-1,551,137
-75% -$26.3M 0.04% 88
2025
Q4
$27.6M Sell
2,059,805
-716,756
-26% -$8.87M 0.11% 68
2025
Q3
$32.7M Sell
2,776,561
-810,918
-23% -$7.56M 0.13% 60
2025
Q2
$23.3M Hold
3,587,479
0.1% 63
2025
Q1
$21M Hold
3,587,479
0.09% 58
2024
Q4
$25M Sell
3,587,479
-325,000
-8% -$2.24M 0.11% 56
2024
Q3
$22.3M Buy
3,912,479
+2,014,154
+106% +$14M 0.1% 60
2024
Q2
$13.7M Buy
1,898,325
+648,450
+52% +$5.67M 0.06% 71
2024
Q1
$11.7M Buy
+1,249,875
New +$7.13M 0.05% 80

Other funds holding DFTX

Blackstone Inc's DFTX Position: Q2 2026 in Review

Blackstone Inc increased its Definium Therapeutics (DFTX) stake by 10% in Q2 2026, buying an estimated $1.31M and bringing the position to 561,612 shares worth $26.4M. The position accounts for 0.08% of the portfolio, ranked #67.

Blackstone Inc first reported a position in DFTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $32.7M in Q3 2025. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Blackstone Inc held 561,612 shares of Definium Therapeutics worth $26.4M as of Q2 2026.
  • Blackstone Inc bought 52,944 Definium Therapeutics shares in Q2 2026, an estimated $1.31M.
  • Definium Therapeutics made up 0.08% of Blackstone Inc's portfolio in Q2 2026, its #67 holding.
  • Blackstone Inc first reported a position in Definium Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Blackstone Inc's Definium Therapeutics position peaked at $32.7M in Q3 2025.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Blackstone Inc's 13F filing for Q2 2026, filed 14 Aug 2026.